Press Releases :: Aerami Therapeutics Holdings, Inc.

Jun 16, 2022 9:00am EDT

Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer

Dec 07, 2021 8:35am EST

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

Nov 18, 2021 8:30am EST

Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer

Nov 11, 2021 8:30am EST

Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors

Aug 25, 2021 9:00am EDT

Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension

Jun 24, 2021 8:00am EDT

Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension

Feb 09, 2021 9:00am EST

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China

Jul 23, 2020 8:00am EDT

Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium

Jun 08, 2020 8:15am EDT

Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline

Feb 05, 2020 8:30am EST

Aerami Therapeutics Appoints Timm Crowder as Chief Operating Officer

rss_feed News RSS